Clinical Trials Logo

Clinical Trial Summary

Background: Functional movement disorder (FMD) causes involuntary movements, such as spasms, shaking, or jerks. These symptoms are not due to a recognized neurological or medical cause. Researchers want to better understand how the brain works to cause these symptoms. Objective: To test if intermittent theta burst stimulation (iTBS) affects brain areas involved in FMD symptoms. Also, to look at the effect of iTBS on mood and motor symptoms. Eligibility: Right-handed people ages 18-65 who have FMD and participated in protocol 07-N-0190 Design: Participants will have 4 visits. In Visit 1, participants will be screened with: Medical history Physical exam Urine test Questionnaires Visit 1 might also include a brain MRI and functional MRI. The MRI scanner is a cylinder surrounded by a strong magnetic field. They will lie on a table that can slide in and out of the cylinder. For the functional MRI, they will be asked to perform tasks during the MRI scan. Visit 2 will be 1-2 weeks after Visit 1. Visits 2, 3, and 4 will be no more than 48 hours apart. These include: Electromyography: Small electrodes are taped to the skin. Muscle activity is recorded while participants receive magnetic stimulation of the brain. Transcranial magnetic stimulation and iTBS: A wire coil is held on the scalp. A brief electrical current passes through the coil and creates a magnetic pulse to stimulate the brain. During iTBS, participants will sit quietly and watch a nature documentary. They will wear earplugs and a cap. MRI Functional MRI Questionnaires


Clinical Trial Description

Objectives: The purpose of this protocol is to investigate feasibility and safety of intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC) in patients with functional movement disorders (FMD). We further aim at exploring whether iTBS of the DLPFC modulates amygdala activity, by investigating iTBS effects on resting-state fronto-amygdala connectivity and on amygdala BOLD response to valenced stimuli. Study population: FMD patients (N=6), aged 18-65 years, admitted at the Human Motor Control Section (HMCS) clinic, who have completed protocol 07-N-0190. Design: Participants will undergo four outpatient visits. On Visit #1 (baseline), patients will undergo a screening session to assess their eligibility to participate in the current study. They will undergo neurological and psychiatric assessment, as well as structural and functional magnetic resonance imaging. Intermittent TBS will be performed on three separated visits (Visit #2, #3 and #4; iTBS1, iTBS 2 and iTBS 3). During each visit, participants will receive three iTBS sessions over 1-hour, with a 15-minute interval between sessions. Each session will last 190 seconds and a total of 600 pulses will be delivered. Magnetic field intensity will be set at 120% of that participants observed daily resting motor threshold. The target will be identified using the neuronavigation system Brainsight. Following each iTBS visit, behavioral and functional imaging data will be collected. Outcome measures: Our primary outcomes will be to evaluate the safety and feasibility of different doses of iTBS of the left DLPFC in patients with FMD. In addition, in order to investigate amygdala engagement by DLPFC iTBS, the following exploratory outcomes will be analyzed: (1) Amygdala BOLD signal change in response to valenced stimuli, from baseline to iTBS3; (2) Amygdala BOLD signal change in response to valenced stimuli, from baseline to each timepoint (iTBS1- iTBS3), for each valence stimuli; (3) Change in fronto-amygdalar resting state functional connectivity, from baseline to iTBS3 (z-score); (4) Change in fronto-amygdalar resting state functional connectivity from baseline to each time point (iTBS1- iTBS3); (5) Change in the valence and arousal subjective levels, using the self-assessment Manikin, from baseline to each time point (iTBS1- iTBS3); (6) Correlations of percent amygdala BOLD signal change with changes in arousal and valence level; (7) Change in the scores on the simplified version of the FMD-RS from pre- to post treatment, for each timepoint. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03263013
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase
Start date March 29, 2018
Completion date February 5, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05623644 - Multimodal MR Imaging Study on ET and PD Patients Subjected With MRgFUS Thalamotomy
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Completed NCT03722212 - Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test N/A
Recruiting NCT05973929 - Movement Disorders in Multiple Sclerosis Patients
Terminated NCT02823158 - Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM N/A
Enrolling by invitation NCT01210781 - Target Planning for Placement of DBS-electrodes and Follow-up of the Clinical Efficacy of Stimulation
Enrolling by invitation NCT00355927 - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. N/A
Completed NCT00037167 - Effects of Exercise Poles on Older Adults During Exercise Walking Phase 1/Phase 2
Recruiting NCT04784494 - MST for Parkinson's Disease N/A
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Recruiting NCT04176692 - The Effects of Muscle Characteristics on the Control of Shoulder Complex During Functional Movements
Recruiting NCT04061135 - Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders N/A
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Completed NCT00500994 - Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures Early Phase 1
Completed NCT04536987 - Robot Therapy for Rehabilitation of Hand Movement After Stroke Phase 2
Recruiting NCT00001208 - Botulinum Toxin for the Treatment of Involuntary Movement Disorders
Completed NCT02392078 - Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Completed NCT00552474 - Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease N/A
Not yet recruiting NCT05032911 - Sensorimotor Control in People With and Without Neck Pain